- Home
- NBH vs PRQR Comparison
NBH vs PRQR Comparison
Compare NBH & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBH
- PRQR
- Stock Information
- Founded
- NBH 2002
- PRQR 2012
- Country
- NBH United States
- PRQR Netherlands
- Employees
- NBH N/A
- PRQR N/A
- Industry
- NBH Finance/Investors Services
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- NBH Finance
- PRQR Health Care
- Exchange
- NBH Nasdaq
- PRQR Nasdaq
- Market Cap
- NBH 292.3M
- PRQR 232.8M
- IPO Year
- NBH N/A
- PRQR 2014
- Fundamental
- Price
- NBH $10.38
- PRQR $2.19
- Analyst Decision
- NBH
- PRQR Strong Buy
- Analyst Count
- NBH 0
- PRQR 8
- Target Price
- NBH N/A
- PRQR $8.88
- AVG Volume (30 Days)
- NBH 85.9K
- PRQR 370.2K
- Earning Date
- NBH 01-01-0001
- PRQR 11-06-2025
- Dividend Yield
- NBH 4.34%
- PRQR N/A
- EPS Growth
- NBH N/A
- PRQR N/A
- EPS
- NBH 0.12
- PRQR N/A
- Revenue
- NBH N/A
- PRQR $20,129,184.00
- Revenue This Year
- NBH N/A
- PRQR N/A
- Revenue Next Year
- NBH N/A
- PRQR N/A
- P/E Ratio
- NBH $87.04
- PRQR N/A
- Revenue Growth
- NBH N/A
- PRQR 8.65
- 52 Week Low
- NBH $8.75
- PRQR $1.07
- 52 Week High
- NBH $11.01
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- NBH 78.98
- PRQR 47.76
- Support Level
- NBH $9.77
- PRQR $2.21
- Resistance Level
- NBH $9.95
- PRQR $2.50
- Average True Range (ATR)
- NBH 0.09
- PRQR 0.14
- MACD
- NBH 0.06
- PRQR -0.01
- Stochastic Oscillator
- NBH 97.60
- PRQR 32.61
About NBH Neuberger Berman Municipal Fund Inc.
Neuberger Berman Municipal Fund Inc is a closed-end management investment company that invests mainly in municipal securities. The company aims to provide common stockholders a high level of current income exempt from Federal income tax.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.